Karsten Henco started his industrial career in the 1980s when he was involved in the establishment of the molecular biology and recombinant DNA technology facilities of BASF AG in Ludwigshafen, Germany. He is co-founder or co-founding investor of fourteen biotech companies in Germany, USA, Canada and Austria, such as Qiagen NV, Evotec AG, NewLab AG, Coley Pharmaceuticals Inc, U3 Pharma AG, Neurimmune Therapeutics AG, HS LifeSciences and QureInvest. He acted as CEO, Chairman or Board member in several of these companies and others, too. Karsten Henco serves as an advisor for HighTech Gründerfonds of the German government. He studied biochemistry in the University of Hannover and at the University of Darmstadt where he was awarded his PhD. Karsten completed his post-doctoral training at Prof. Charles Weissmann’s lab in the University of Zürich, Switzerland.